NCT03082885View on ClinicalTrials.gov

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

June 2, 2019

Study Completion Date

July 30, 2019

Conditions
Liver Failure
Interventions
DRUG

Thymosin-α1

1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.

Trial Locations (1)

510630

Third Affliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03082885 - The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF | Biotech Hunter | Biotech Hunter